Medicare Physician Data-driven Performance Payment System Act of 2026
Summary
HR8622 is an early-stage bill referred to two committees with no text available and no explicit funding authorization. It has minimal near-term market impact until substantive provisions are released and legislative momentum builds.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8622 is in the earliest legislative stage with no bill text available
- 2.No funding is authorized or appropriated by this bill
- 3.Market impact is negligible until substantive provisions emerge
Market Implications
No actionable market implications at this stage. Investors should monitor committee markups and the release of bill text for specific physician payment reform mechanisms. The lack of cosponsors and early referral status suggest this is a low-priority bill with uncertain legislative trajectory.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
Repair Abuses of MSP Payments (RAMP) Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.